<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03687905</url>
  </required_header>
  <id_info>
    <org_study_id>Fatma</org_study_id>
    <nct_id>NCT03687905</nct_id>
  </id_info>
  <brief_title>Proliferative Lupus Nephritis Treatment With Chloroquine and Hydroxychloroquine</brief_title>
  <official_title>Comparative Study Between Chloroquine and Hydroxychloroquine as Therapeutic Modalities for Children and Adolescents With Proliferative Lupus Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation the efficacy of chloroquine and hydroxychloroquine in the treatment of
      proliferative lupus nephritis class III and IV in children and adolescents and evaluate the
      side effects of both drugs .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will fulfill the diagnostic criteria of SLE. The diagnosis of systemic lupus
      erythematosus is based on clinical and laboratory criteria. The criteria set developed by the
      American College of Rheumatology (ACR) and diagnosed wih lupus nephritis class III and IV .

      Inclusion Criteria:

        -  Children and adolescents who fulfill diagnostics criteria of SLE and diagnosed with
           lupus nephritis class III and IV.

        -  All patients will be received steroids , MMF and Angiotensin Converting Enzyme.

      Exclusion Criteria:

        -  Patients diagnosed with lupus nephritis class I,II,V and VI.

        -  Patients received Cyclophosphamide in stead of MMF.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Fundus examination as screening test</measure>
    <time_frame>12 months</time_frame>
    <description>Detection of chloroquine and hydroxychloroquine related retinal toxicity at early stage.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Proliferative Nephritis</condition>
  <condition>Chloroquine Retinopathy</condition>
  <arm_group>
    <arm_group_label>Lupus nephritis III or IV/chloroquine</arm_group_label>
    <description>receiving chloroquine with daily dose 5 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lupus nephritis III or IV/hydroxychloroquine</arm_group_label>
    <description>receiving hydroxycholorquine with daily dose 5 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Systemic lupus erythematosus</arm_group_label>
    <description>not received hydroxychloroquine nor chloroquine .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine</intervention_name>
    <description>group1 received chloroquine .</description>
    <arm_group_label>Lupus nephritis III or IV/chloroquine</arm_group_label>
    <other_name>alexoquine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Group 2 received hydroxychloroquine</description>
    <arm_group_label>Lupus nephritis III or IV/hydroxychloroquine</arm_group_label>
    <other_name>hydroquine</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        â€¢ All patients will fulfill the diagnostic criteria of SLE. The diagnosis of systemic lupus
        erythematosus is based on clinical and laboratory criteria. The criteria set developed by
        the American College of Rheumatology (ACR) and diagnosed wih lupus nephritis class III and
        IV
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children and adolescents who fulfill diagnostics criteria of SLE and diagnosed with
             lupus nephritis class III and IV.

          -  All patients will be received steroids , MMF and Angiotensin Converting Enzyme.

        Exclusion Criteria:

          -  Patients diagnosed with lupus nephritis class I,II,V and VI.

          -  Patients received Cyclophosphamide in stead of MMF.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Fatma S Gheet, M.B.,BCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tanta University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fatma S Gheet, M.B.,BCh</last_name>
    <phone>+201148157993</phone>
    <email>fatmagheet@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fatma Gheet</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fatma S Gheet, M.B.,BCh</last_name>
      <phone>+201148157993</phone>
      <email>fatmagheet@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 18, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2018</study_first_posted>
  <last_update_submitted>September 25, 2018</last_update_submitted>
  <last_update_submitted_qc>September 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Fatma Sayed Ahmed Gheet</investigator_full_name>
    <investigator_title>Resident Pediatercian</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Chloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data is secret.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

